US · CDTX · BIOTECHNOLOGY
Cidara Therapeutics, Inc. (CDTX) intrinsic value and stock valuation
$221.38as of 2026-01-08 · Mkt cap 2.48B
Data updated · price as of 2026-01-08
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cidara Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values CDTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CDTX’s statements →
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Disc Medicine, Inc. (IRON) $88.31
- Legend Biotech Corporation (LEGN) $32.01
- Zai Lab Limited (ZLAB) $24.80
- Scholar Rock Holding Corporation (SRRK) $27.99
- Adaptive Biotechnologies Corporation (ADPT) $17.59
- Mineralys Therapeutics, Inc. (MLYS) $39.65
- Catalyst Pharmaceuticals, Inc. (CPRX) $21.38
- IDEAYA Biosciences, Inc. (IDYA) $29.66
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
- CEO
- Jeffrey L. Stein
- Employees
- 38
- Beta
- 1.55
Explore
Frequently asked questions
What is the intrinsic value of Cidara Therapeutics, Inc. (CDTX)?
InvestorsCraft does not currently publish an intrinsic value for CDTX. How the IC value is calculated.
Is CDTX undervalued?
InvestorsCraft does not publish an undervaluation signal for CDTX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Aug 12, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.